Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 9Other hematologic neoplasm 7Gynecologic 5Gastrointestinal 5Myeloid 4Genitourinary 2CNS 2Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Tyrosine Kinase Inhibitors × Gynecologic × Clear all
NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Sun Yat-sen University

Phase 1/2 Completed
29 enrolled
Gynecologic

Ovarian Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
30 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
32 enrolled
Gynecologic

Endometrial Neoplasms

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
123 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

NCT05422183 2022-06-16

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Zhongda Hospital

Phase 2 Unknown
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡